AGIX KraneShares Artificial Intelligence ETF

AtheroGenics Inc (NASDAQ: AGIX) announces the following Webcast: What: AtheroGenics Inc First Quarter 2006 Earnings Conference Call Webcast When: April 20, 2006 @ 09:00 AM Eastern Where: http://www.investorcalendar.com/EventPage.asp?ID=103324 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Donna Glasky, (678)336-2517 or investor@atherogenics.com If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=103324 or http://www.investorcalendar.com/ AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being studied in a pivotal Phase III clinical trial called ARISE (Aggressive Reduction of Inflammation Stops Events). AGI-1067 is the first oral agent that directly targets specific genes underlying the chronic inflammatory process within vessel walls of coronary arteries called atherosclerosis, the disease process that leads to coronary heart disease and the leading cause of death in the U.S. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma using its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit http://www.atherogenics.com